Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease

OBJECTIVES: Interleukin-23 (IL-23) has emerged as a new therapeutic target for the treatment of inflammatory bowel disease (IBD). As biomarkers of disease state and treatment efficacy are becoming increasingly important in drug development, we sought to identify efficacy biomarkers for anti-IL-23 th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cayatte, Corinne, Joyce-Shaikh, Barbara, Vega, Felix, Boniface, Katia, Grein, Jeffrey, Murphy, Erin, Blumenschein, Wendy M, Chen, Smiley, Malinao, Maria-Christina, Basham, Beth, Pierce, Robert H, Bowman, Edward P, McKenzie, Brent S, Elson, Charles O, Faubion, William A, Malefyt, Rene de Waal, Kastelein, Robert A, Cua, Daniel, McClanahan, Terrill K, Beaumont, Maribel
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Inflammatory Bowel Disease
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3365674/
https://ncbi.nlm.nih.gov/pubmed/23238132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ctg.2012.2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars